To verify the alternative TLR3 signaling, breast cancer cells were pretreated with MyD88 inhibitor (ST2825) for 4 h followed by stimulation of TLR3 by the addition of the TLR3 ligand. This evidence concerns the gene TLR3 and breast carcinoma.